Ronald de Wit

42.0k total citations · 10 hit papers
373 papers, 26.4k citations indexed

About

Ronald de Wit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ronald de Wit has authored 373 papers receiving a total of 26.4k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 172 papers in Pulmonary and Respiratory Medicine and 168 papers in Surgery. Recurrent topics in Ronald de Wit's work include Prostate Cancer Treatment and Research (152 papers), Bladder and Urothelial Cancer Treatments (98 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Ronald de Wit is often cited by papers focused on Prostate Cancer Treatment and Research (152 papers), Bladder and Urothelial Cancer Treatments (98 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Ronald de Wit collaborates with scholars based in Netherlands, United States and France. Ronald de Wit's co-authors include Mario A. Eisenberger, Ian F. Tannock, Kim N., Christine Théodore, Stéphane Oudard, Mark Rosenthal, Nicholas D. James, A Płużańska, William R. Berry and J Horti and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Ronald de Wit

363 papers receiving 25.8k citations

Hit Papers

Docetaxel plus Prednisone... 2003 2026 2010 2018 2004 2012 2017 2017 2008 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
    2004 4.3k citations Ian F. Tannock, Ronald de Wit et al. New England Journal of Medicine profile →
  2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Karim Fizazi, Fred Saad et al. New England Journal of Medicine profile →
  3. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →
  4. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    2017 939 citations Daniel Castellano, Ronald de Wit et al. profile →
  5. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
    2008 820 citations Ronald de Wit, Mario A. Eisenberger et al. Journal of Clinical Oncology profile →
  6. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
    2003 593 citations Ronald de Wit et al. Journal of Clinical Oncology profile →
  7. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
    2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
  8. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    2019 377 citations Ronald de Wit, Johann S. de Bono et al. New England Journal of Medicine profile →
  9. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    2021 329 citations Joost L. Boormans, Ronald de Wit et al. profile →
  10. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
    2019 306 citations Joaquim Bellmunt, Cora N. Sternberg et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ronald de Wit 13.4k 10.2k 9.2k 4.5k 4.5k 373 26.4k
Daniel P. Petrylak 10.7k 0.8× 11.1k 1.1× 7.5k 0.8× 4.9k 1.1× 3.4k 0.8× 529 23.1k
Cora N. Sternberg 21.0k 1.6× 12.1k 1.2× 10.6k 1.2× 7.6k 1.7× 6.6k 1.5× 583 34.5k
Christopher J. Logothetis 9.6k 0.7× 7.9k 0.8× 3.9k 0.4× 6.9k 1.5× 3.7k 0.8× 458 20.8k
Nicholas J. Vogelzang 22.7k 1.7× 17.2k 1.7× 10.1k 1.1× 8.4k 1.8× 6.5k 1.4× 701 41.8k
John D. Hainsworth 12.3k 0.9× 21.5k 2.1× 5.3k 0.6× 10.1k 2.2× 5.2k 1.2× 631 37.1k
Fred Saad 23.9k 1.8× 15.4k 1.5× 5.3k 0.6× 7.6k 1.7× 6.9k 1.6× 1.2k 36.7k
Maha Hussain 13.3k 1.0× 6.2k 0.6× 2.7k 0.3× 3.7k 0.8× 4.5k 1.0× 361 18.5k
Walter M. Stadler 14.1k 1.0× 9.4k 0.9× 4.4k 0.5× 11.9k 2.6× 7.2k 1.6× 473 26.8k
Karim Fizazi 25.3k 1.9× 14.8k 1.4× 5.0k 0.5× 6.5k 1.4× 8.0k 1.8× 835 36.7k
Allan T. van Oosterom 10.1k 0.8× 9.3k 0.9× 4.3k 0.5× 4.5k 1.0× 2.8k 0.6× 89 21.9k

Countries citing papers authored by Ronald de Wit

Since Specialization
Citations

This map shows the geographic impact of Ronald de Wit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald de Wit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald de Wit more than expected).

Fields of papers citing papers by Ronald de Wit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald de Wit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald de Wit. The network helps show where Ronald de Wit may publish in the future.

Co-authorship network of co-authors of Ronald de Wit

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald de Wit. A scholar is included among the top collaborators of Ronald de Wit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald de Wit. Ronald de Wit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Talebi, Zahra, Yan Jin, Alice A. Gibson, et al.. (2024). Darolutamide does not interfere with OATP‐mediated uptake of docetaxel. International Journal of Cancer. 155(2). 314–323. 3 indexed citations
2.
Mostert, Bianca, Jaco Kraan, Vanja de Weerd, et al.. (2023). mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer. Molecular Oncology. 17(9). 1898–1907. 5 indexed citations
3.
Salhi, Yazan Al, Debbie Robbrecht, Ronald de Wit, et al.. (2023). The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial. BMC Cancer. 23(1). 539–539. 1 indexed citations
4.
Stevens, Michiel, Anouk Mentink, Frank Coumans, et al.. (2023). Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product. Molecular Oncology. 19(7). 2133–2143. 2 indexed citations
5.
Weerd, Vanja de, Jaco Kraan, John W.M. Martens, et al.. (2023). Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. JCO Precision Oncology. 7(7). e2300156–e2300156. 1 indexed citations
6.
Wit, Ronald de, Stephen J. Freedland, Stéphane Oudard, et al.. (2022). Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. Prostate Cancer and Prostatic Diseases. 26(1). 67–73. 7 indexed citations
7.
Delanoy, Nicolas, Debbie Robbrecht, Mario A. Eisenberger, et al.. (2021). Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers. 13(6). 1284–1284. 5 indexed citations
8.
Wit, Ronald de, Jourik A. Gietema, Gerard Groenewegen, et al.. (2020). Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy. European Urology Open Science. 19. e405–e406.
9.
Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations
10.
Wit, Ronald de, Bertrand Tombal, & Stephen J. Freedland. (2020). Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer. European Urology. 79(2). 170–172. 5 indexed citations
11.
Wit, Ronald de, Johann S. de Bono, Cora N. Sternberg, et al.. (2019). Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine. 381(26). 2506–2518. 377 indexed citations breakdown →
12.
Nieuweboer, Annemieke J.M., Anne‐Joy M. de Graan, Paul Hamberg, et al.. (2016). Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clinical Cancer Research. 23(7). 1679–1683. 12 indexed citations
13.
Wit, Ronald de, Claire M. Spillman, Harry H. Hendon, et al.. (2013). Dynamical seasonal prediction of climate extremes in the Pacific. Piantadosi, J., Anderssen, R.S. and Boland J. (eds) MODSIM2013, 20th International Congress on Modelling and Simulation. 1 indexed citations
14.
15.
Wit, Ronald de, Iwona Skoneczna, Gedske Daugaard, et al.. (2012). Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983. Journal of Clinical Oncology. 30(8). 792–799. 47 indexed citations
16.
Armstrong, Andrew J., Elizabeth Garrett‐Mayer, Ronald de Wit, Ian F. Tannock, & Mario A. Eisenberger. (2009). Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research. 16(1). 203–211. 166 indexed citations
17.
18.
Armstrong, Andrew J., et al.. (2007). A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clinical Cancer Research. 13(21). 6396–6403. 282 indexed citations
19.
Leeuwen, Flora E. van, Alexandra W. van den Belt‐Dusebout, Gabey M. Ouwens, et al.. (2005). Long-term risk of non-germ cell malignancies in 5-year survivors of testicular cancer. Data Archiving and Networked Services (DANS). 1 indexed citations
20.
Wit, Ronald de, Paul Wilkinson, PHM de Mulder, et al.. (1999). Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study. UCL Discovery (University College London). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel P. Petrylak Breakdown of academic impact, for papers by Cora N. Sternberg Breakdown of academic impact, for papers by Christopher J. Logothetis Breakdown of academic impact, for papers by Nicholas J. Vogelzang Breakdown of academic impact, for papers by John D. Hainsworth Breakdown of academic impact, for papers by Fred Saad Breakdown of academic impact, for papers by Maha Hussain Breakdown of academic impact, for papers by Walter M. Stadler Breakdown of academic impact, for papers by Karim Fizazi Breakdown of academic impact, for papers by Allan T. van Oosterom
Rankless by CCL
2026